Aurora Daljit Singh sold 57,670 shares of Neumora Therapeutics, Inc. at $1.51 for −$86.8k on Aug 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
See Remarks
See Remarks
Filed Aug 19, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$86,822.19Shares × reported price
Shares traded
57,670Common Stock
Price per share
$1.51Reported price. Read footnotes for ranges.
% of reported position traded
41.06%This security and ownership context
Holdings after
82,770Direct
Trade date
Aug 17, 2026Sell
Filed
Aug 19, 2026, 7:17 PM ET2-day reporting delay
Accession
0001610717-26-000362Code S · Transaction 12165
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 140,440 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

NMRA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NMRA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −1.8%1w ago −1.2%1d ago −2.4%
Returns since7d −4.9%30d −55%90d180d1y

Footnotes in full

F1: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.5277, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries. F4: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5: The stock option is fully vested and exercisable. F6: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. F7: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. F8: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. F9: This transaction was executed in multiple trades at prices ranging from $1.49 to $1.645, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F10: This transaction was executed in multiple trades at prices ranging from $1.48 to $1.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F11: This transaction was executed in multiple trades at prices ranging from $1.62 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F12: This transaction was executed in multiple trades at prices ranging from $1.62 to $1.7006, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F13: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.